Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

CNS Drugs

Volumn 25, Issue 10, 2011, Pages 859-885

  Singh, Surendra P ^a,b   Singh, Vidhi ^c  

^a Dorothy Pattison Hospital   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c MediWare Computer Software Engineering   (United Kingdom)

Author keywords

Acetylcysteine; Alanine; CX 516; Cycloserine; Glutamate receptor modulators; Glycine; Memantine; Meta analysis; Sarcosine; Schizophrenia; Serine.

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ANTIDEPRESSANT AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; GLYCINE; MEMANTINE; MOLINDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE; SARCOSINE;

ADD ON THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COCHRANE LIBRARY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS (TOPIC); NEUROMODULATION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; GLYCINE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOSINE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 80052996482     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11586650-000000000-00000     Document Type: Article

References (197)

1. Collingridge GL, Olsen RW, Peters J, et al. A nomenclature for ligand-gated ion channels. Neuropharmacology 2009; 56 (1): 2-5
2. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11 (3): 327-35 (Pubitemid 32524098)
3. Coyle JT, Tsai G. TheNMDAreceptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl.) 2004; 174 (1): 32-8 (Pubitemid 38925088)
4. Labrie V, Roder JC. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 2010; 34 (3): 351-72
5. Xu T, Gong N. Glycine and glycine receptor signaling in hippocampal neurons: diversity, function and regulation. Prog Neurobiol 2010; 91 (4): 349-61
6. Chaves C, Marque CR, Trzesniak C, et al. Glutamate-Nmethyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res 2009; 42 (11): 1002-14
7. Appaji Rao N, Ambili M, Jala VR, et al. Structurefunction relationship in serine hydroxymethyltransferase. Biochim Biophys Acta 2003; 1647 (1-2): 24-9
8. Wolosker H, Dumin E, Balan L, et al. D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. FEBS J 2008; 275 (14): 3514-26
9. De Miranda J, Panizzutti R, Foltyn VN, et al. Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine. Proc Natl Acad Sci USA 2002; 99 (22): 14542-7 (Pubitemid 35257707)
10. Foltyn VN, Bendikov I, De Miranda J, et al. Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity. J Biol Chem 2005; 280 (3): 1754-63
11. Schell MJ, Brady RO, Molliver ME, et al. D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci 1997; 17 (5): 1604-15 (Pubitemid 27089806)
12. Shoji K, Mariotto S, Ciampa AR, et al. Regulation of serine racemase activity by D-serine and nitric oxide in human glioblastoma cells. Neurosci Lett 2006; 392 (1-2): 75-8 (Pubitemid 41757579)
13. Mustafa AK, van Rossum DB, Patterson RL, et al. Glutamatergic regulation of serine racemase via reversal of PIP2 inhibition. Pro Natl Acad Sci USA 2009; 106 (8): 2921-6
14. Rutter AR, Fradley RL, Garrett EM, et al. Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur J Neurosci 2007; 25 (6): 1757-66 (Pubitemid 46550015)
15. Cubelos B, Gonzá lez-Gonzá lez IM, Gime´nez C, et al. The scaffolding protein PSD-95 interacts with the glycine transporter GLYT1 and impairs its internalization. J Neurochem 2005; 95 (4): 1047-58 (Pubitemid 41713489)
16. Raiteri L, Raiteri M. Functional 'glial' GLYT1 glycine transporters expressed in neurons. J Neurochem 2010; 14 (3): 647-53
17. Lane H, Lin C, Huang Y, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (Nmethylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13 (4): 451-60
18. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26 (4-6): 365-84
19. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987; 9 (1): 12-35
20. Deutsch SI, Mastropaolo J, Schwartz BL, et al. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12 (1): 1-13 (Pubitemid 19058128)
21. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48 (7): 627-40
22. Breier A, Adler CM, Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998; 29 (2): 142-7 (Pubitemid 28221792)
23. Krystal JH, Perry EB, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62 (9): 985-94
24. Harsing LG, Gacsalyi I, Szabo G, et al. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 2003; 74 (4): 811-25 (Pubitemid 36351646)
25. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010; 83 (3-4): 108-21
26. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009; 23 (2): 91-101
27. Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50 (7): 521-30 (Pubitemid 32971883)
28. Erhardt S, Blennow K, Nordin C, et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313 (1-2): 96-8 (Pubitemid 32973903)
29. Kapoor R, Lim KSY, Cheng A, et al. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res 2006; 1106 (1): 205-10 (Pubitemid 44177639)
30. Hashimoto K, Engberg G, Shimizu E, et al. Reduced Dserine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 (5): 767-9 (Pubitemid 40897791)
31. Bendikov I, Nadri C, Amar S, et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90 (1-3): 41-51 (Pubitemid 46177566)
32. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60 (6): 572-6 (Pubitemid 36682314)
33. Ohnuma T, Sakai Y, Maeshima H, et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1905-12
34. Sumiyoshi T, Anil AE, Jin D, et al. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 2004; 7 (1): 1-8 (Pubitemid 38523801)
35. Neeman G, Blanaru M, Bloch B, et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 2005; 162 (9): 1738-40 (Pubitemid 41318246)
36. Sumiyoshi T, Jin D, Jayathilake K, et al. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol 2005; 8 (3): 451-5 (Pubitemid 41002499)
37. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Pro Natl Acad Sci USA 2002; 99 (21): 13675-80 (Pubitemid 35215440)
38. Goldberg TE, Straub RE, Callicott JH, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006; 31 (9): 2022-32
39. Jansen A, Krach S, Krug A, et al. A putative high risk diplotype of the G72 gene is in healthy individuals asso-ciated with better performance in working memory functions and altered brain activity in the medial temporal lobe. Neuroimage 2009; 45 (3): 1002-8
40. Do KQ, Cabungcal JH, Frank A, et al. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009; 19 (2): 220-30
41. Davies KJ. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000; 50 (4-5): 279-89 (Pubitemid 32289086)
42. Kannan R, Kuhlenkamp JF, Jeandidier E, et al. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 1990; 85 (6): 2009-13 (Pubitemid 20192980)
43. Sagara JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial cells. J Neurochem 1993; 61 (5): 1672-6 (Pubitemid 23317188)
44. Gegg ME, Beltran B, Salas-Pino S, et al. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 2003; 86 (1): 228-37 (Pubitemid 36753863)
45. Dean OM, van den Buuse M, Bush AI, et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009; 16 (23): 2965-76
46. Janáky R, Dohovics R, Saransaari P, et al. Modulation of [3H]dopamine release by glutathione in mouse striatal slices. Neurochem Res 2007; 32 (8): 1357-64 (Pubitemid 46988197)
47. Tosic M, Ott J, Barral S, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006; 79 (3): 586-92 (Pubitemid 44384270)
48. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007; 104 (42): 16621-6 (Pubitemid 350211066)
49. Scheffer R, Diamond BI, Correnti EE, et al. Plasma lipid peroxidation and HVA in first episode psychosis [abstract]. Biol Psychiatry 1995; 37 (9): 681
50. RaffaM,Mechri A, Othman LB, et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (7): 1178-83
51. Radonjić NV, Knezević ID, Vilimanovich U, et al. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology 2010; 58 (4-5): 739-45
52. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008; 295 (4): C849-68
53. Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 2010; 13 (2): 257-71
54. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64 (5): 361-8
55. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51 (3): 199-214 (Pubitemid 24081509)
56. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl.) 2004; 174 (1): 39-44 (Pubitemid 38925089)
57. Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41: 237-60 (Pubitemid 32385889)
58. Patil ST, Zhang L,Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial.NatMed 2007; 13 (9): 1102-7 (Pubitemid 47517511)
59. Abi-Saab WM, D'Souza DC, Moghaddam B, et al. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31 Suppl. 2: 104-9 (Pubitemid 28396279)
60. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20 (3): 201-25 (Pubitemid 29067401)
61. Fricker A, Mok MHS, de la Flor R, et al. Effects of N- acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009; 56 (6-7): 1060-7
62. Wengenack TM, Curran GL, Poduslo JF. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res 1997; 754 (1-2): 46-54 (Pubitemid 27170250)
63. Breese GR, Knapp DJ, Moy SS. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 2002; 26 (4): 441-55 (Pubitemid 36158662)
64. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003; 1003: 318-27 (Pubitemid 38083065)
65. Bubeníková-Valesová V, Horácek J, Vrajová M, et al. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008; 32 (5): 1014-23
66. Di Maria E, Gulli R, Begni S, et al. Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study. Am J Med Genet B Neuropsychiatr Genet 2004; 128B (1): 27-9 (Pubitemid 38849913)
67. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005; 5: 26
68. Pandurangi AK, Dalkilic A. Polypharmacy with secondgeneration antipsychotics: a review of evidence. J Psychiatr Pract 2008; 14 (6): 345-67
69. Siris S, Pollack S, Bermanzohn P, et al. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia. Schizophr Res 2000; 44 (3): 187-92 (Pubitemid 30657956)
70. Patrick V, Schleifer SJ, Nurenberg JR, et al. Best practices: an initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006; 57 (1): 21-3 (Pubitemid 43053830)
71. Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001; 16 (2): 87-92 (Pubitemid 32171833)
72. Jockers-Scherü bl MC, Bauer A, Godemann F, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2005; 20 (1): 27-31 (Pubitemid 40105546)
73. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010; 197 (3): 174-9
74. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006; (2): CD003730
75. Tsai GE, Lin P. Strategies to enhance N-methyl-Daspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010; 16 (5): 522-37
76. American Psychiatric Association.Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000
77. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17 (1): 1-12 (Pubitemid 26120810)
78. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991; 17 (2): 289-309
79. Alfredsson G, Wiesel FA. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl.) 1989; 99 (3): 322-7 (Pubitemid 19244108)
80. Lovett Doust JW, Huszka L. Influence of some psychoactive drugs on mineral metabolism in man. Int Pharmacopsychiatry 1973; 8 (3): 159-72
81. Antun FT, Burnett GB, Cooper AJ, et al. The effects of L-methionine (without MAOI) in schizophrenia. J Psychiatr Res 1971; 8 (2): 63-71
82. Lindenmayer JP. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr Scand Suppl 1995; 388: 15-9
83. Zylberman I, Javitt DC, Zukin SR. Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia. Ann N Y Acad Sci 1995; 757: 487-91
84. Goff DC, Tsai G, Manoach DS, et al. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.AmJ Psychiatry 1995; 152 (8): 1213-5
85. Javitt DC, Zylberman I, Zukin SR, et al. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151 (8): 1234-6 (Pubitemid 24240973)
86. Rosse RB, Fay-McCarthy M, Kendrick K, et al. Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol 1996; 19 (5): 444-50 (Pubitemid 26314863)
87. Heresco-Levy U, Javitt DC, Ermilov M, et al. Doubleblind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169 (5): 610-7
88. Goff DC, Tsai G, Manoach DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153 (12): 1628-30 (Pubitemid 26406177)
89. van Berckel BN, Hijman R, van der Linden JA, et al. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996; 40 (12): 1298-300 (Pubitemid 27006415)
90. Heresco-Levy U, Silipo G, Javitt DC. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996; 32 (4): 731-40 (Pubitemid 26428278)
91. Eastwood SL, Kerwin RW, Harrison PJ. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry 1997; 41 (6): 636-43 (Pubitemid 27157754)
92. Malhotra AK, Pinals DA, Adler CM, et al. Ketamineinduced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17 (3): 141-50 (Pubitemid 27365955)
93. Malhotra AK, Adler CM, Kennison SD, et al. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42 (8): 664-8 (Pubitemid 27444500)
94. Spurlock G, Williams J, McGuffin P, et al. European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms. Am J Med Genet 1998; 81 (1): 24-8 (Pubitemid 28114846)
95. van Berckel BN, Lipsch C, Gispen-de Wied C, et al. The partialNMDAagonist D-cycloserine stimulates LHsecretion in healthy volunteers. Psychopharmacology (Berl.) 1998; 138 (2): 190-7 (Pubitemid 28330837)
96. Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44 (11): 1081-9 (Pubitemid 28547143)
97. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56 (1): 21-7 (Pubitemid 29055046)
98. Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56 (1): 29-36 (Pubitemid 29055047)
99. Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156 (1): 145-7 (Pubitemid 29034896)
100. Goff DC, Henderson DC, Evins AE, et al. A placebocontrolled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45 (4): 512-4 (Pubitemid 29130454)
101. Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21 (1): 17-27 (Pubitemid 29253832)
102. van Berckel BN, EvenblijCN, van Loon BJ, et al.D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 1999; 21 (2): 203-10 (Pubitemid 29304581)
103. Adler CM, Malhotra AK, Elman I, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156 (10): 1646-9 (Pubitemid 29460002)
104. Tsai GE, Yang P, Chung LC, et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156 (11): 1822-5 (Pubitemid 29517581)
105. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, et al. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther 1999; 24 (5): 369-74 (Pubitemid 29520787)
106. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-Daspartate receptor antagonists. Arch Gen Psychiatry 2000; 57 (3): 270-6 (Pubitemid 30140436)
107. Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157 (5): 826-8 (Pubitemid 30249667)
108. Heresco-Levy U, Javitt DC, Ermilov M, et al. Doubleblind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1998; 1 (2): 131-5 (Pubitemid 128538374)
109. Lahti AC, Warfel D, Michaelidis T, et al. Long-term outcome of patients who receive ketamine during research. Biol Psychiatry 2001; 49 (10): 869-75 (Pubitemid 32436391)
110. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44 (2): 95-8
111. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21 (5): 484-7 (Pubitemid 32937430)
112. Tortorella A, Monteleone P, Fabrazzo M, et al. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001; 44 (4): 167-71 (Pubitemid 33036026)
113. Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive highdose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 2001; 4 (4): 385-91 (Pubitemid 33151682)
114. Heresco-Levy U, Ermilov M, Shimoni J, et al. Placebocontrolled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002; 159 (3): 480-2 (Pubitemid 34184748)
115. Evins AE, Amico E, Posever TA, et al. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 2002; 56 (1-2): 19-23 (Pubitemid 34655463)
116. Marenco S, Egan MF, Goldberg TE, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 2002; 57 (2-3): 221-6 (Pubitemid 35240024)
117. Bressan RA, Erlandsson K,Mulligan RS, et al. Evaluation ofNMDAreceptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings. Ann N Y Acad Sci 2003; 1003: 364-7 (Pubitemid 38083072)
118. Heresco-Levy U, ErmilovM, Lichtenberg P, et al.High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55 (2): 165-71 (Pubitemid 38367720)
119. Tsai G, Lane H, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55 (5): 452-6 (Pubitemid 38338531)
120. van der Heijden FMMA, Tuinier S, FekkesD, et al. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004; 14 (3): 259-65 (Pubitemid 38410961)
121. Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004; 66 (2-3): 89-96 (Pubitemid 38041106)
122. Padmos RC, Bekris L, Knijff EM, et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry 2004; 56 (7): 476-82 (Pubitemid 39278244)
123. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71 (2-3): 239-48 (Pubitemid 39330502)
124. Goff DC, Herz L, Posever T, et al. A six-month, placebocontrolled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl.) 2005; 179 (1): 144-50 (Pubitemid 40576701)
125. Northoff G, Richter A, Bermpohl F, et al. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res 2005; 72 (2-3): 235-48 (Pubitemid 39550994)
126. Lane H, Hsu S, Liu Y, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005; 25 (1): 6-11 (Pubitemid 40129376)
127. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005; 162 (2): 394-6 (Pubitemid 40216226)
128. Yurgelun-Todd DA, Coyle JT, Gruber SA, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res 2005; 138 (1): 23-31 (Pubitemid 40228959)
129. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57 (6): 577-85 (Pubitemid 40409697)
130. Diaz P, Bhaskara S, Dursun SM, et al. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25 (3): 277-8 (Pubitemid 40685796)
131. Holcomb HH, Lahti AC, Medoff DR, et al. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005; 30 (12): 2275-82 (Pubitemid 41643980)
132. Tsai GE, Yang P, Chang Y, et al. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59 (3): 230-4 (Pubitemid 43208969)
133. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006; 11 (2): 118-9 (Pubitemid 43164609)
134. Silver H, Goodman C, Isakov V, et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 2005; 20 (6): 319-26 (Pubitemid 41475322)
135. Lane H, Chang Y, Liu Y, et al. Sarcosine or D-serine addon treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005; 62 (11): 1196-204 (Pubitemid 41586919)
136. Fujii K, Maeda K, Hikida T, et al. Serine racemase binds to PICK1: potential relevance to schizophrenia. Mol Psychiatry 2006; 11 (2): 150-7 (Pubitemid 43164616)
137. Lane H, Huang C, Wu P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60 (6): 645-9 (Pubitemid 44402375)
138. Schwab SG, Knapp M, Sklar P, et al. Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 2006; 11 (9): 837-46 (Pubitemid 44299105)
139. Schosser A, Aschauer HN, Wildenauer DB, et al. Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007; 144B (3): 347-50 (Pubitemid 46642026)
140. Goff DC, Lamberti JS, Leon AC, et al. A placebocontrolled add-on trial of
141. Lane H, Liu Y, Huang C, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, doubleblind study. Biol Psychiatry 2008; 63 (1): 9-12 (Pubitemid 350234891)
142. Fathalli F, Rouleau GA, Xiong L, et al. No association between the DRD3 Ser9Gly polymorphism and schizophrenia. Schizophr Res 2008; 98 (1-3): 98-104 (Pubitemid 350235883)
143. Krivoy A, Weizman A, Laor L, et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol 2008; 18 (2): 117-21 (Pubitemid 350296846)
144. Cerullo MA, Adler CM, Strakowski SM, et al. Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study. Schizophr Res 2007; 97 (1-3): 294-6 (Pubitemid 350088392)
145. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164 (10): 1593-602 (Pubitemid 350069740)
146. Kim B, Choi EY, Kim CY, et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008; 23 (1): 61-7 (Pubitemid 351166069)
147. Leung S, Croft RJ, O'Neill BV, et al. Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls. Psychopharmacology (Berl.) 2008; 196 (3): 451-60 (Pubitemid 351191176)
148. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; 33 (9): 2187-99 (Pubitemid 351992093)
149. Renou J, De Luca V, Zai CC, et al. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Mol Psychiatry 2007; 12 (12): 1058-60 (Pubitemid 350191368)
150. Stone JM, Erlandsson K, Arstad E, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl.) 2008; 197 (3): 401-8
151. Fuchs SA,De BarseMMJ, Scheepers FE, et al. Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. Eur Neuropsychopharmacol 2008; 18 (5): 333-8
152. Popp J, Leucht S, Heres S, et al. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009; 9 (1): 71-7
153. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009; 14 (8): 804-19
154. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly Dcycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106 (2-3): 320-7
155. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34 (5): 1322-9
156. Djurovic S, Kä hler AK, Kulle B, et al. A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE). Schizophr Res 2009; 107 (2-3): 242-8
157. Zai CC, Tiwari AK, De Luca V, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009; 19 (5): 317-28
158. Ohi K, Hashimoto R, Yasuda Y, et al. Association study of the G72 gene with schizophrenia in a Japanese population: a multicenter study. Schizophr Res 2009; 109 (1-3): 80-5
159. Chen S, Shen Y, Chen C. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (3): 470-4
160. Fijal BA,Kinon BJ,Kapur S, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009; 9 (5): 311-8
161. de LucenaD, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebocontrolled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70 (10): 1416-23
162. de Lucena D, Fernandes BS, Kunz M, et al. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine. J Clin Psychiatry 2010; 71 (1): 91-2
163. Hatano T, Ohnuma T, Sakai Y, et al. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Psychiatry Res 2010; 177 (1-2): 27-31
164. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121 (1-3): 125-30
165. Daumann J, Wagner D, Heekeren K, et al. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol (Oxford) 2010; 24 (10): 1515-24
166. Liem-Moolenaar M, Zoethout RWM, de Boer P, et al. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J Psychopharmacol (Oxford) 2010; 24 (11): 1681-7
167. Hwang R, Zai C, Tiwari A, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010; 10 (3): 200-18
168. Liem-Moolenaar M, Zoethout RWM, de Boer P, et al. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. J Psychopharmacol (Oxford) 2010; 24 (11): 1671-9
169. Strzelecki D, Rabe-Jabońska J. Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients [in Polish]? Psychiatr Pol 2010; 44 (3): 395-404
170. Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry 2011; 72 (1): 34-42
171. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index. Norwegian Institute of Public Health, 2009 [online]. Available from URL: http://www. whocc.no/atc-ddd-index/[Accessed 2011 Mar 7]
172. Wampold BE, Mondin GW, Moody M, et al. A metaanalysis of outcome studies comparing bona fide psychotherapies: empirically, "all must have prizes". Psychol Bull 1997; 122 (3): 203-15
173. Winkley K, Ismail K, Landau S, et al. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2006; 333 (7558): 65
174. Cooper H. The handbook of research synthesis and metaanalysis. 2nd ed. New York (NY): Russell Sage Foundation, 2009: 271
175. van Buuren S, Groothuis-Oudshoorn K. MICE-version 2.1: multivariate imputation by chained equations. 2009 [online]. Available from URL: http://www.stefvanbuuren. nl/[Accessed 2011 Mar 7]
176. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2009
177. Viechtbauer W. Metafor-version 0.5-7: meta-analysis package for R. 2009 [online]. Available from URL: http://www.jstatsoft.org/v36/i03/[Accessed 2011 Mar 7]
178. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Ed Behav Stat 2005; 30 (3): 261-93 (Pubitemid 41538934)
179. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): L. Erlbaum Associates, 1988
180. Schü nemann HJ, Oxman AD, Vist GE, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester (UK): Wiley-Blackwell, 2008: 359-84
181. Rosenthal R. Meta-analysis: a review. Psychosom Med 1991; 53 (3): 247-71
182. Randolph JJ, Edmondson RS. Using the binomial effect size display (BESD) to present the magnitude of effect sizes to the evaluation audience. Practical Assess Res Eval 2005; 10: 1-7
183. Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004; 8 (4): 283-91 (Pubitemid 38859657)
184. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5 (2): e45
185. Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. Epub 2011 Feb 3
186. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156 (7): 990-9 (Pubitemid 29302789)
187. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60 (6): 553-64 (Pubitemid 36682312)
188. Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008; 258 (1): 16-27
189. The´berge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in firstepisode schizophrenia. Br J Psychiatry 2007; 191: 325-34 (Pubitemid 47555981)
190. Kentaro I, Nobuhiro K, Kaori O, et al. Assessment of acute adverse events of glycine ingestion at a high dose in human volunteers. J Urban Living Health Assoc 2006; 50 (1): 27-32
191. Online archive on glycine. CID-750[uid]. PubChem (public chemical) database, 2010 [online]. Available from URL: http://pubchem.ncbi.nlm.nih.gov/ summary/summary.cgi? cid=750 [Accessed 2011 Mar 7]
192. Online archive on D-serine. CID-71077[uid]. PubChem (public chemical) database, 2010 [online]. Available from URL: http://pubchem.ncbi.nlm.nih.gov/ summary/sum mary.cgi?cid=71077[Accessed 2011 Mar 7]
193. Heresco-Levy U. D-serine monotherapy for schizophrenia. Jerusalem: Ezrath Nashim-Herzog Memorial Hospital, 2009
194. Bergeron R, Meyer TM, Coyle JT, et al. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Pro Natl Acad Sci USA 1998; 95 (26): 15730-4 (Pubitemid 29018768)
195. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003; 89 (2): 691-703 (Pubitemid 36206118)
196. Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5- methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010; 53 (12): 4603-14
197. ZhangHX,HyrcK, Thio LL. The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J Physiol (Lond.) 2009; 587 (13): 3207-20